|
1.
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Chen C-Z: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Noguchi S, Mori T, Hoshino Y, et al:
MicroRNA-143 functions as a tumor suppressor in human bladder
cancer T24 cells. Cancer Lett. 307:211–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Pallante P, Visone R, Ferracin M, et al:
MicroRNA deregulation in human thyroid papillary carcinomas. Endocr
Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Iorio MV, Ferracin M, Liu CG, et al:
MicroRNA gene expression deregulation in human breast cancer.
Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Shi W, Gerster K, Alajez NM, et al:
MicroRNA-301 mediates proliferation and invasion in human breast
cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Tang D, Zhang Q, Zhao S, et al: The
expression and clinical significance of microRNA-1258 and
heparanase in human breast cancer. Clin Biochem. 46:926–932. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Sampath D, Liu C, Vasan K, et al: Histone
deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b
in chronic lymphocytic leukemia. Blood. 119:1162–1172. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Musumeci M, Coppola V, Addario A, et al:
Control of tumor and microenvironment cross-talk by miR-15a and
miR-16 in prostate cancer. Oncogene. 30:4231–4242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Cai C-K, Zhao G-Y, Tian L-Y, et al:
miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and
cell cycle arrest in osteosarcoma. Oncol Rep. 28:1764–1770.
2012.PubMed/NCBI
|
|
14.
|
Diniz MG, Gomes CC, de Castro WH, et al:
miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic
tumors. Cell Oncol. 35:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Yang J, Cao Y, Sun J and Zhang Y: Curcumin
reduces the expression of Bcl-2 by upregulating miR-15a and miR-16
in MCF-7 cells. Med Oncol. 27:1114–1118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Spruck CH, Won KA and Reed SI: Deregulated
cyclin E induces chromosome instability. Nature. 401:297–300. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi
K and Bedrosian I: Cyclin E deregulation is an early event in the
development of breast cancer. Breast Cancer Res Treat. 115:651–659.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Keyomarsi K, Tucker SL, Buchholz TA, et
al: Cyclin E and survival in patients with breast cancer. N Engl J
Med. 347:1566–1575. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Sgambato A, Camerini A, Collecchi P, et
al: Cyclin E correlates with manganese superoxide dismutase
expression and predicts survival in early breast cancer patients
receiving adjuvant epirubicin-based chemotherapy. Cancer Sci.
100:1026–1033. 2009. View Article : Google Scholar
|
|
20.
|
Goretti E, Rolland-Turner M, Leonard F,
Zhang L, Wagner DR and Devaux Y: MicroRNA-16 affects key functions
of human endothelial progenitor cells. J Leukoc Biol. 93:645–655.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
22.
|
Bryan BB, Schnitt SJ and Collins LC:
Ductal carcinoma in situ with basal-like phenotype: a possible
precursor to invasive basal-like breast cancer. Mod Pathol.
19:617–621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ljungberg BJ, Jacobsen J, Rudolfsson SH,
Lindh G, Grankvist K and Rasmuson T: Different vascular endothelial
growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression
profiles between clear cell and papillary renal cell carcinoma. BJU
Int. 98:661–667. 2006. View Article : Google Scholar
|
|
24.
|
Tryfonopoulos D, Walsh S, Collins DM, et
al: Src: a potential target for the treatment of triple-negative
breast cancer. Ann Oncol. 22:2234–2240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Oliveras-Ferraros C, Vazquez-Martin A,
Lopez-Bonet E, et al: Growth and molecular interactions of the
anti-EGFR antibody cetuximab and the DNA cross-linking agent
cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in
the treatment of triple-negative/basal-like breast cancer. Int J
Oncol. 33:1165–1176. 2008.
|
